NetraMark Achieves Major FDA Milestone
(CNSX:AIAI),(OTC US:AINMF),(Other OTC:AINMF),(Boerse Frankfurt – Freiverkehr:PF0),(CNSX:AIAI.CN), TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation […]